EVMN Evommune, Inc.
$9.51▼ -4.80%
Healthcare
Other
Volume 241.8K
Avg Volume (10D) 866.1K
Key Metrics & Fundamentals
Market Cap
$345.14M
P/E Ratio
–
Div Yield
–%
52W Range
9.46 - 33.20
% vs 50 MA
-20.82%
% vs 200 MA
-49.22%
RSI-14
30.3
MACD Histogram
-0.3000
Beta (1Y vs SPY)
1.03
Free Cash Flow
-$20.50M
Gross Rev
$0
Gross Profit
$0
EBITDA
-$34.34M
COGS
–
Operating Exp
$34.90M
Operating Income
-$34.90M
EBIT
-$34.90M
Pretax Income
-$32.25M
Net Income
-$32.25M
EPS (Diluted)
-0.89
Price & Volume History
Loading chart…
Recent News
Karyopharm pushes off debt payment; Amgen eyes broader Imdelltra use
BioPharma Dive · Sep 11, 2026 9:37 AM
Sector Update: Healthcare Stocks Decline in Afternoon Trading
MT Newswires · Sep 9, 2026 5:34 PM
This Biotech Has Lost 50%-Plus On Just One Drug; Why It's Still Trucking On
Investor's Business Daily · Sep 9, 2026 2:01 PM
Sector Update: Healthcare Stocks Mixed Premarket Wednesday
MT Newswires · Sep 9, 2026 1:16 PM
Evommune Halts Atopic Dermatitis Program Following Trial Failure
Benzinga · Sep 9, 2026 11:40 AM
Evommune Atopic Dermatitis Phase 2b Trial Misses Endpoints; Shares Down Pre-Bell
MT Newswires · Sep 9, 2026 10:07 AM
Why Is EVMN Stock Down 13% After-Hours?
Stocktwits · Sep 8, 2026 11:51 PM
Evommune Announces Top-line Results from EVO756 Phase 2b Trial in Moderate-to-Severe Atopic Dermatitis
Business Wire · Sep 8, 2026 9:43 PM
Needham Initiates Evommune at Buy With $28 Price Target
MT Newswires · Aug 26, 2026 11:29 AM
RBC Adjusts PT on Evommune to $29 From $30, Maintains Outperform Speculative Risk Rating
MT Newswires · Aug 7, 2026 12:46 PM
Financial Overview - Income Statement
Quarterly
Sep 2025
See EVMN's money flow as a full page
Social Sentiment
Avg -0.40 · 1 posts
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.